[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yi Yang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":366},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,46,69,96,120,143,162,185,204,222,242,260,280,308,328,347],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100596210","efficacy-and-safety-of-plasma-adsorption-combined-with-evt-for-ais-lvo-100596210",false,"NCT07042490","Efficacy and Safety of Plasma Adsorption Combined With EVT for AIS-LVO","Efficacy and Safety of Plasma Adsorption Combined With Endovascular Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion of Anterior Circulation: A Multicenter, Randomized, Parallel-controlled Clinical Trial","PROMOTE-EVT","Inclusion Criteria:\n\n1. Age 18-80 years, male or female.\n2. Diagnosis of acute ischemic stroke within 12 hours of symptom onset, underwent endovascular thrombectomy (EVT) adhering to current guidelines for large vessel occlusion in the anterior circulation (confirmed by DSA as ICA,MCA-M1,MCA-M2,ACA-A1,ACA-A2 occlusion or tandem lesion) and achieve successful recanalization (mTICI grade 2b\u002F3).\n3. Baseline NIHSS after EVT ≥ 6 and ≤25 points.\n4. Randomization and the first plasma adsorption can be initiated within 12 hours after EVT.\n5. Pre-stroke mRS≤ 2 points.\n6. Patient\u002Flegally family members have signed the Informed consent form.\n\nExclusion Criteria:\n\n1. Imaging after EVT indicated malignant brain edema with midline shift or brain herniation and surgical treatment was planned.\n2. Parenchymal hemorrhage type 1, or type 2 confirmed by CT.\n3. Allergic to any ingredient of the plasma separator, the adsorption device, or the piping.\n4. Contraindications to plasma adsorption, platelet count \\\u003C60×10\\^9\u002FL,white blood cell\\\u003C4×10\\^9\u002FL, uncontrolled hypertension with persistent systolic blood pressure ≥200 mmHg or diastolic blood pressure ≥110 mmHg, uncontrolled hypotension, systolic blood pressure \\\u003C90 mmHg or diastolic blood pressure \\\u003C60 mmHg.\n5. Previous history of malignant tumors, autoimmune diseases or being treated with immunosuppressants, hormones, or tumor necrosis factor inhibitors.\n6. Previous history of organic heart disease and NYHA Class III or IV.\n7. Currently taking anticoagulant(dabigatran, rivaroxiban, warfarin, etc.), previous history of serious hematological system disorders, or abnormal coagulation function (international normalized ratio \\[INR\\], activated partial thromboplastin time \\[APTT\\], prothrombin time \\[PT\\] upper limit of the normal range).\n8. Severe liver and kidney dysfunction or abnormal laboratory test results（serum aspartate aminotransferase or alanine aminotransferase \\>3 times the upper limit of normal, serum creatinine\\>265umol\u002Fl(\\>3mg\u002Fdl)）.\n9. Pregnancy , lactation or life expectancy of less than 3 months or inability to complete the study for other reasons.\n10. Unwilling to be followed up or poor compliance.\n11. Current or past participation in other clinical research, or participation in this study within 3 months prior to admission.\n12. Other conditions that the researchers think make the patient unsuitable for the study.","ALL","18 Years","80 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this study is to determine the efficacy and safety of plasma adsorption for patients of acute ischemic stroke who underwent endovascular thrombectomy due to large vessel occlusion of anterior circulation.",[28,29],"Acute Ischemic Stroke From Large Vessel Occlusion","Endovascular Thrombectomy",[31,32,29],"Acute ischemic stroke","Plasma adsorption","NOT_YET_RECRUITING","2025-06-27",{"date":36,"type":37},"2025-06-29","ACTUAL",{"date":39,"type":22},"2025-06-30",{"date":41,"type":22},"2027-06-30",{"name":43,"class":44},"Yi Yang","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":45},"100588481","itbs-for-acute-ischemic-stroke-after-thrombectomy-100588481","NCT06941961","iTBS for Acute Ischemic Stroke After Thrombectomy","Efficacy and Safety of Intermittent Theta Burst Stimulation in Acute Anterior Circulation Ischemic Stroke Patients Undergoing Mechanical Thrombectomy","Inclusion Criteria:\n\n* 1\\) Age 18-85 years, regardless of gender.\n* 2\\) Acute ischemic stroke caused by occlusion of the anterior circulation large vessels (internal carotid artery, M1 or M2 segment of the middle cerebral artery), verified by CTA or DSA.\n* 3\\) Mechanical thrombectomy (MT) performed within 24 hours of symptom onset.\n* 4\\) Successful Reperfusion: Post-MT eTICI score ≥ 2b.\n* 5\\) NIHSS score 5-25 at 24 hours post-MT, with ≥2 points in at least one limb.\n\nExclusion Criteria:\n\n* 1\\) Pre-stroke modified Rankin Scale (mRS) score ≥2.\n* 2\\) PH2-type intracranial hemorrhage on brain CT post-MT.\n* 3\\) Patients who underwent intracranial stent placement during MT.\n* 4\\) Contraindications to iTBS: History of epilepsy or seizures, implanted cardiac pacemakers, cochlear implants, or other electronic\u002Fmagnetic-sensitive devices.\n* 5\\) Severe consciousness impairment, cognitive dysfunction, or psychiatric disorders preventing compliance with iTBS.\n* 6\\) Expected survival \\\u003C3 months due to other medical conditions or inability to complete follow-up for any reason.\n* 7\\) Participation in another interventional study.\n* 8\\) Any other condition deemed unsuitable for enrollment by the investigator.","85 Years",{"count":55,"type":22},178,[25],"The goal of this randomized, single-blind, parallel-controlled clinical trial is to evaluate the efficacy and safety of intermittent theta burst stimulation (iTBS) as an adjunctive therapy for acute anterior circulation ischemic stroke patients who have undergone successful mechanical thrombectomy (MT). The study population includes adults aged 18-85 with NIHSS scores 5-25 post-MT and eTICI≥2b reperfusion.",[59],"Ischemic Stroke","RECRUITING","2025-04-28",{"date":63,"type":37},"2025-04-30",{"date":65,"type":37},"2025-04-25",{"date":67,"type":22},"2026-08-01",{"name":43,"class":44},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":23,"phases":78,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":4},"100570084","safety-and-efficacy-of-remote-ischemic-conditioning-in-patients-with-chronic-internal-carotid-artery-occlusion-receiving-hybird-surgery-a-pilot-randomized-controlled-trial-100570084","NCT06702644","Safety and Efficacy of Remote Ischemic Conditioning in Patients with Chronic Internal Carotid Artery Occlusion Receiving Hybird Surgery: a Pilot, Randomized Controlled Trial","SERIC-HS","Inclusion Criteria:\n\n* Age≥18 years, regardless of sex\n* Patients with chronic carotid artery occlusion who are going to undergo hybird surgery\n* Can cooperate with and complete brain magnetic resonance imaging (MRI) examination\n* Signed and dated informed consent is obtained\n\nExclusion Criteria:\n\n* Hemorrhagic stroke\n* Severe cardiac dysfunction or arrhythmia\n* Uncontrolled hypertension (defined as systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg, despite medication taken at enrollment)\n* Severe hepatic and renal dysfunction (defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥3 times higher than the upper limit of the normal range, creatinine \\>265umol\u002Fl (3mg\u002Fdl))\n* The patients who have the contraindication of remote ischemic conditioning treatment, such as severe soft tissue injury, fracture or vascular injury in the upper limb. Acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc.\n* Pregnant or lactating women\n* He\u002FShe is participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to admission\n* Other conditions that the researchers think are not suitable for the group",{"count":77,"type":22},60,[25],"The purpose of this study is to explore the safety and efficacy of remote ischemic conditioning in patients with internal carotid artery occlusion receiving hybird surgery.",[81],"Carotid Artery Occlusion",[83,84,85,86,87],"RIC","remote ischemic conditioning","carotid artery occlusion","hybird surgery","interventional surgery","2024-11-25",{"date":90,"type":37},"2024-11-26",{"date":92,"type":22},"2024-12-01",{"date":94,"type":22},"2027-03-31",{"name":43,"class":44},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":45},"100565695","phase-4-safety-and-efficacy-of-edaravone-dexborneol-for-acute-ischemic-stroke-100565695","NCT06645522","Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke","Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years old and ≤ 80 years old, regardless of gender;\n2. Patients diagnosed as acute ischemic stroke according to \"key points for diagnosis of all kinds of major cerebrovascular diseases in China 2019\", and able to randomise and initiate edaravone dexborneol treatment less than or equal to 48 hours of stroke onset.\n3. Total National Institute of Health stroke scale (NIHSS)≥6 and ≤24, and the sum of NIHSS score for the upper limb and the lower limb is greater than or equal to 2;\n4. modified Rankin Scale (mRS) score of 1 or less before onset.\n5. Did not receive edaravone dexborneol treatment before enrollment;\n6. The informed consent approved by the ethics committee was voluntarily signed by the patient or his legal representative.\n\nExclusion Criteria:\n\n1. Reperfusion therapy (intravenous thrombolysis and endovascular therapy) has been received or planned after stroke onset.\n2. Transient ischemic attack (TIA);\n3. Posterior circulation stroke;\n4. Intracranial hemorrhagic diseases seen in head imaging: hemorrhagic stroke, epidural hematoma, intracranial hematoma, intraventricular hemorrhage, subarachnoid hemorrhage, etc;\n5. Severe disturbance of consciousness: the item score of 1a consciousness level of NIHSS was more than 1;\n6. Patients with severe mental disorders and dementia;\n7. Systolic blood pressure after blood pressure control is still higher than 220mmhg or diastolic blood pressure was higher than 120mmhg;\n8. Severe cardiac insufficiency, dissection and acute pericarditis; Severe liver insufficiency, ALT or AST \\> 3.0 × ULN; Or severe active liver diseases have been diagnosed, such as acute hepatitis, chronic active hepatitis, cirrhosis, etc;Severe renal insufficiency, Serum Creatinine (SCr) is greater than 200μmol\u002FL, Creatinine Clearance (CrCl) is less than 30 ml\u002Fmin or receiving hemodialysis; Or suffering from severe systemic diseases, the estimated survival time is less than 90 days;\n9. Complicated with malignant tumor or undergoing anti-tumor treatment;\n10. Therapeutic neuroprotective agents have been applied after onset of stroke, including commercially available edaravone, nimodipine, ganglioside, citicoline, piracetam, butyl benzene peptides, Urinary Kallidinogenase, Ginkgolide.\n11. Patients during pregnancy, lactation and planned pregnancy;\n12. Allergic to dexborneol or edaravone or excipients;\n13. Have participated in other clinical studies or are participating in other clinical studies within 30 days before randomization;\n14. Patients who are unwilling to be followed up，and the investigators consider the patients are not suitable for this trial.",{"count":104,"type":22},1200,[106],"PHASE4","The purpose of this study is to determine the efficacy and safety of edaravone dexborneol in treating acute ischemic stroke.",[109],"Acute Ischemic Stroke",[109,111],"Edaravone Dexborneol","2024-10-15",{"date":114,"type":37},"2024-10-17",{"date":116,"type":22},"2024-10-30",{"date":118,"type":22},"2027-01-30",{"name":43,"class":44},{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":17,"minAge":127,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":23,"phases":129,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":140,"leadSponsor":142,"locationsCount":45},"100507160","effects-of-rtms-on-the-anxiety-state-of-older-patients-with-gad-100507160","NCT05883774","Effects of rTMS on the Anxiety State of Older Patients With GAD","Effects of Repetitive Transcranial Magnetic Stimulation on the Anxiety State of Older Patients With Generalized Anxiety Disorder","Inclusion Criteria:\n\n* 1）Age≥60 years, regardless of gender.\n* 2）Meets the diagnostic criteria for generalized anxiety disorder in the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-V) developed by the American Psychiatric Association.\n* 3）HAMA score≥14 and HAMD-17 items score \\\u003C17.\n* 4）No adjustment in the type and dose of anti-anxiety medication in the 3 months prior to randomization.\n* 5）Willing to participate and sign the informed consent.\n\nExclusion Criteria:\n\n* 1）Traumatic brain injury or other conditions affecting the brain, such encephalitis, brain tumors, or intracranial hypertension.\n* 2）Previous history of epilepsy, family history of epilepsy or presence of seizure provoking factors or alcohol abuse.\n* 3）History of other psychiatric disorders such as current post-traumatic stress disorder, substance use disorder (within 6 months), bipolar disorder and obsessive-compulsive disorder.\n* 4）Unstable mental state with impulses toward self-harm or suicide.\n* 5）Presence of intracranial metal implant, cochlear implant, built-in pulse generator (such as cardiac pacemaker), etc.\n* 6）Medical or surgical disorders that are severe or unstable.\n* 7）Pregnancy or breastfeeding.\n* 8\\) Those who are participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to enrollment.\n* 9\\) Other conditions that the researchers think are not suitable for the project.","60 Years",{"count":21,"type":22},[25],"The purpose of this study is to evaluate the effects of low-frequency repetitive transcranial magnetic stimulation on anxiety state in older patients with generalized anxiety disorder.",[132],"Generalized Anxiety Disorder",[134,135],"repetitive transcranial magnetic stimulation","generalized anxiety disorder","2024-10-01",{"date":138,"type":37},"2024-10-02",{"date":92,"type":22},{"date":141,"type":22},"2025-12-01",{"name":43,"class":44},{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":149,"maxAge":53,"enrollmentInfo":150,"targetDuration":4,"studyType":23,"phases":152,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":45},"100504254","effects-of-remote-ischemic-conditioning-on-blood-pressure-in-older-patients-with-hypertension-100504254","NCT05845905","Effects of Remote Ischemic Conditioning on Blood Pressure in Older Patients With Hypertension","Inclusion Criteria:\n\n* 1\\) Age ≥65 years and ≤85 years, regardless of gender;\n* 2\\) History of essential hypertension and clinical systolic blood pressure ≥ 140 mmHg, regardless of whether they are receiving antihypertensive medication;\n* 3\\) Willing to participate and sign the informed consent.\n\nExclusion Criteria:\n\n* 1\\) Secondary hypertension;\n* 2\\) Clinical blood pressure ≥ 180\u002F110 mmHg or 24-hour mean arterial pressure ≥ 170\u002F100 mmHg;\n* 3\\) Severe organ dysfunction or failure;\n* 4\\) Severe hematologic disorders or significant coagulation abnormalities;\n* 5\\) History of atrial fibrillation or myocardial infarction within 6 months;\n* 6\\) Individuals who had contraindication of remote ischemic conditioning, such as severe soft tissue injury, fracture or vascular injury in the upper limb, acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc;\n* 7\\) Individuals who will or have received anticoagulant therapy with drugs such as dabigatran, rivaroxaban, warfarin, etc;\n* 8\\) Those who are participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to enrollment;\n* 9\\) Other conditions that the researchers think are not suitable for the project.","65 Years",{"count":151,"type":22},158,[25],"The purpose of this study is to learn about effects of remote ischemic conditioning on blood pressure in older patients with essential hypertension.",[155],"Essential Hypertension",{"date":138,"type":37},{"date":158,"type":37},"2023-05-10",{"date":160,"type":22},"2024-12-31",{"name":43,"class":44},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":169,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":23,"phases":172,"briefSummary":173,"conditions":174,"keywords":176,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":179,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":45},"100500573","effectiveness-of-digital-health-management-on-patients-with-head-and-neck-vascular-stenosis-100500573","NCT05798013","Effectiveness of Digital Health Management on Patients With Head and Neck Vascular Stenosis","Effectiveness of Digital Health Management on Patients With Head and Neck Vascular Stenosis: A Multicenter, Cluster Randomized Controlled Trial Based on Chinese Population","Inclusion Criteria:\n\n1. Inclusion criteria of the clusters\n\n   Hospitals with the qualification of \"head and neck ultrasound center\" in China.\n2. Inclusion criteria for individuals\n\n   * (1)Age ≥ 35 years old, with no restriction on gender.\n   * (2)Patients with clinically diagnosed head and neck stenosis or occlusion, including mild, moderate or severe stenosis or occlusion of the carotid artery and mild, moderate or severe stenosis or occlusion of the intracranial artery.\n   * (3)Ability to use a smartphone and have a mobile application installed on the handset.\n   * (4)Subjects or their legal representatives agreed to the study and signed the project informed consent form.\n\nExclusion Criteria:\n\n1. Exclusion criteria for the clusters\n\n   The included centers did not have the capacity to undertake the trial.\n2. Exclusion criteria for individuals\n\n   * (1)Combination of severe systemic diseases such as respiratory failure, renal failure, gastrointestinal bleeding, coagulation dysfunction, malignancy, etc.\n   * (2)Patients with a life expectancy of less than 2 years or who are unable to complete the study for other reasons.","35 Years",{"count":171,"type":22},102072,[25],"The purpose of this study is to evaluate the effectiveness of digital health management for intervention on Chinese population with head and neck vascular stenosis.",[175],"Head and Neck Vascular Stenosis",[177,178],"head and neck vascular stenosis","digital health management",{"date":138,"type":37},{"date":181,"type":22},"2025-10",{"date":183,"type":22},"2028-10",{"name":43,"class":44},{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":23,"phases":193,"briefSummary":194,"conditions":195,"keywords":196,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":199,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":203,"locationsCount":45},"100496259","safety-and-efficacy-of-levofloxacin-combined-with-intravenous-thrombolysis-for-acute-ischemic-stroke-100496259","NCT05741905","Safety and Efficacy of Levofloxacin Combined With Intravenous Thrombolysis for Acute Ischemic Stroke","Inclusion Criteria:\n\n1. Age 18-75 years.\n2. Acute ischemic stroke patients underwent intravenous thrombolysis, treated with ateplase (0.9mg\u002Fkg)\n3. mRS≤1 before stroke onset, NIHSS ≥ 5 and ≤ 15，la (NIHSS) level of consciousness \\\u003C 1\n\nExclusion Criteria:\n\n1. Endovascular treatment\n2. Patients using glucocorticoids, antiarrhythmic drugs (class I and class III antiarrhythmic drugs: quinidine, procaine amine, lidocaine, phenytoin sodium, verapamil, etc.), and quinolones within 14 days;\n3. Patients with other diseases that may aggravate adverse drug reactions, such as ventricular arrhythmias, prolonged QT interval (male: QTc\\>430ms, female: QTc\\>450ms), severe cardiac insufficiency (NYHA functional grade ≥ III), myasthenia gravis, peripheral neuropathy, seizures, tendon-related diseases, severe immune system-related diseases, hematological diseases, active hepatitis or cirrhosis, serious respiratory diseases;\n4. Abnormal liver and kidney function: glutamic oxaloacetic transaminase or glutamic pyruvic transaminase exceeds 3 times the upper limit of normal; Direct bilirubin or indirect bilirubin more than 3 times the normal upper limit; Blood creatinine exceeds 1.1 times the upper limit of normal; Creatinine clearance rate≤50ml\u002Fmin; Urea nitrogen≥ 20mg\u002FdL;\n5. Concurrent infection;\n6. Fasting blood glucose lower than 3.9 mmol\u002FL;\n7. Patients with symptomatic intracranial hemorrhage confirmed by clinical signs and imaging before randomization;\n8. Patients allergy to fluoroquinolones or other antibiotics;\n9. Patients with a life expectancy less than 3 months or patients unable to complete the study for other reasons;\n10. Not willing to be followed up or poor treatment compliance;\n11. Patients who are participating in other clinical studies, or have participated in other clinical studies within 3 months before enrollment, or have participated in this study;\n12. Other conditions not suitable for enrollment.","75 Years",{"count":21,"type":22},[25],"The purpose of this study is to determine the efficacy and safety of levofloxacin combined with intravenous thrombolysis in treating acute ischemic stroke",[109],[31,197,198],"Intravenous thrombolysis","Levofloxacin",{"date":138,"type":37},{"date":201,"type":37},"2023-06-01",{"date":160,"type":22},{"name":43,"class":44},{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":191,"enrollmentInfo":211,"targetDuration":4,"studyType":23,"phases":212,"briefSummary":213,"conditions":214,"keywords":215,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":216,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":45},"100500674","safety-and-efficacy-of-levofloxacin-for-acute-ischemic-stroke-100500674","NCT05799326","Safety and Efficacy of Levofloxacin for Acute Ischemic Stroke","Safety and Efficacy of Levofloxacin for Acute Ischemic Stroke: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. Age 18-75 years.\n2. The patients were clinically diagnosed with acute ischemic stroke with NIHSS score ≥5 points and ≤15 points,and NHISS score 1a level of consciousness \\\u003C 1 point.\n3. mRS≤1 before stroke onset.\n4. Signed and dated informed consent is obtained.\n\nExclusion Criteria:\n\n1. Patients with transient ischemic attack and those undergoing emergency reperfusion therapy, including intravenous thrombolysis and emergency thrombectomy.\n2. Patients using glucocorticoids, antiarrhythmic drugs (class I and class III antiarrhythmic drugs: quinidine, procaine amine, lidocaine, phenytoin sodium, verapamil, etc.), and quinolones within 14 days.\n3. Patients with other diseases that may aggravate adverse drug reactions, such as ventricular arrhythmias, prolonged QT interval (male: QTc\\>430ms, female: QTc\\>450ms), severe cardiac insufficiency (NYHA functional grade ≥ III), myasthenia gravis, peripheral neuropathy, seizures, tendon-related diseases, severe immune system-related diseases, hematological diseases, active hepatitis or cirrhosis, serious respiratory diseases.\n4. Abnormal liver and kidney function: glutamic oxaloacetic transaminase or glutamic pyruvic transaminase exceeds 3 times the upper limit of normal; Direct bilirubin or indirect bilirubin more than 3 times the normal upper limit; Blood creatinine exceeds 1.1 times the upper limit of normal; Creatinine clearance rate≤50ml\u002Fmin; Urea nitrogen≥ 20mg\u002FdL.\n5. Concurrent infection.\n6. Blood glucose lower than 3.9 mmol\u002FL.\n7. Patients allergy to fluoroquinolones or other antibiotics.\n8. Patients with a life expectancy less than 3 months or patients unable to complete the study for other reasons.\n9. Not willing to be followed up or poor treatment compliance.\n10. Patients who are participating in other clinical studies, or have participated in other clinical studies within 3 months before enrollment, or have participated in this study.\n11. Other conditions not suitable for enrollment.",{"count":21,"type":22},[25],"The purpose of this study is to determine the efficacy and safety of levofloxacin in treating acute ischemic stroke.",[109],[31,198],{"date":138,"type":37},{"date":218,"type":37},"2023-06-30",{"date":220,"type":22},"2024-12-30",{"name":43,"class":44},{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":191,"enrollmentInfo":229,"targetDuration":4,"studyType":23,"phases":231,"briefSummary":232,"conditions":233,"keywords":234,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":236,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":4},"100496351","safety-and-efficacy-study-of-levofloxacin-combined-with-endovascular-thrombectomy-for-acute-ischemic-stroke-100496351","NCT05743101","Safety and Efficacy Study of Levofloxacin Combined With Endovascular Thrombectomy for Acute Ischemic Stroke","Safety and Efficacy Study of Levofloxacin Combined With Endovascular Thrombectomy for Acute Ischemic Stroke Due to Large Vessel Occlusion of Anterior Circulation","Inclusion Criteria:\n\n1. Age 18-75 years.\n2. Patients with clinically confirmed acute ischemic stroke within 24 hours after onset, CTA or DSA confirmed anterior circulation large vessel occlusion (ICA, M1\u002Fproximal M2 segment of MCA, tandem lesions), met the current guidelines for emergency endovascular interventional therapy, and underwent emergency thrombectomy.\n3. mRS≤1 before stroke onset.\n4. Signed and dated informed consent is obtained.\n\nExclusion Criteria:\n\n1. Patients with contraindications to emergency thrombectomy;\n2. The head CT showed large facial cerebral infarction;\n3. Patients using glucocorticoids, antiarrhythmic drugs (class I and class III antiarrhythmic drugs: quinidine, procaine amine, lidocaine, phenytoin sodium, verapamil, etc.), and quinolones within 14 days;\n4. Patients with other diseases that may aggravate adverse drug reactions, such as ventricular arrhythmias, prolonged QT interval (male: QTc\\>430ms, female: QTc\\>450ms), severe cardiac insufficiency (NYHA functional grade ≥ III), myasthenia gravis, peripheral neuropathy, seizures, tendon-related diseases, severe immune system-related diseases, hematological diseases, active hepatitis or cirrhosis, serious respiratory diseases;\n5. Abnormal liver and kidney function: glutamic oxaloacetic transaminase or glutamic pyruvic transaminase exceeds 3 times the upper limit of normal; Direct bilirubin or indirect bilirubin more than 3 times the normal upper limit; Blood creatinine exceeds 1.1 times the upper limit of normal; Creatinine clearance rate≤50ml\u002Fmin; Urea nitrogen≥ 20mg\u002FdL;\n6. Fasting blood glucose lower than 3.9 mmol\u002FL;\n7. Patients allergy to fluoroquinolones or other antibiotics;\n8. Patients with a life expectancy less than 3 months or patients unable to complete the study for other reasons;\n9. Not willing to be followed up or poor treatment compliance;\n10. Patients who are participating in other clinical studies, or have participated in other clinical studies within 3 months before enrollment, or have participated in this study;\n11. Other conditions not suitable for enrollment.",{"count":230,"type":22},80,[25],"The purpose of this study is to determine the efficacy and safety of levofloxacin combined with endovascular thrombectomy in treating acute ischemic stroke due to large vessel occlusion of anterior circulation.",[109],[235],"Endovascular thrombectomy, Levofloxacin",{"date":138,"type":37},{"date":238,"type":22},"2025-05-01",{"date":240,"type":22},"2026-07-01",{"name":43,"class":44},{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":246,"acronym":247,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":249,"targetDuration":4,"studyType":23,"phases":251,"briefSummary":252,"conditions":253,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":254,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":45},"100337146","safety-and-efficacy-of-remote-ischemic-conditioning-in-patients-with-acute-ischemic-stroke-100337146","NCT03669653","Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Ischemic Stroke","SERIC-AIS","Inclusion Criteria:\n\n* 1）Age≥18 years, \\\u003C 80 years, regardless of sex；\n* 2）Patients with clinically definite diagnosis of acute ischemic stroke and able to commence RIC treatment within 12 hours of stroke onset\n* 3）Baseline NIHSS score\\>5, and≤25 ；\n* 4）GCS score ≥8；\n* 5）Signed and dated informed consent is obtained\n\nExclusion Criteria:\n\n* 1\\) Patients with suspected posterior circulation infarction；\n* 2\\) Patients who undergo thrombolytic therapy or endovascular treatment；\n* 3\\) mRS≥2 score before the onset of the disease；\n* 4\\) Double upper limbs or lower limbs paralysis was found in this case；\n* 5）Active bleeding of organs within 6 months of admission or current, including cerebral hemorrhage, subarachnoid hemorrhage, gastrointestinal hemorrhage, fundus hemorrhage and so on；\n* 6\\) Other intracranial lesions, such as cerebrovascular malformation cerebral venous diseases, tumor and other diseases involving the brain；\n* 7\\) Treated blood pressure ≤90mmHg\u002F60mmHg or≥180mmHg\u002F100mmHg；\n* 8\\) Severe organ dysfunction or failure；\n* 9\\) Persons suffering from severe hematological diseases or severe coagulation disorder dysfunction；\n* 10\\) Those who had a history of severe trauma or had major surgery within 6 months prior to admission；\n* 11\\) The patients who had the contraindication of remote ischemic conditioning treatment, such as severe soft tissue injury, fracture or vascular injury in the upper limb；Acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc；\n* 12\\) Pregnant or lactating women；\n* 13\\) Previous remote ischemic conditioning therapy or similar treatment；\n* 14\\) Patients with a life expectancy of less than 3 months or patients unable to complete the study for other reasons；\n* 15\\) Severe hepatic and renal dysfunction\n* 16\\) Unwilling to be followed up or treated for poor compliance；\n* 17\\) He\u002FShe is participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to admission；\n* 18\\) Other conditions that the researchers think are not suitable for the group.",{"count":250,"type":22},912,[25],"he purpose of this study is to determine the efficacy and safety of remote ischemic conditioning for acute ischemic stroke.",[109],{"date":138,"type":37},{"date":256,"type":22},"2025-06-17",{"date":258,"type":22},"2026-09-20",{"name":43,"class":44},{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":23,"phases":269,"briefSummary":270,"conditions":271,"keywords":273,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":274,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":45},"100322976","safety-and-efficacy-of-remote-ischemic-conditioning-in-patients-with-spontaneous-intracerebral-hemorrhage-100322976","NCT03484936","Safety and Efficacy of Remote Ischemic Conditioning in Patients With Spontaneous Intracerebral Hemorrhage","SERIC-sICH","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Supratentorial intracerebral hemorrhage confirmed by brain CT scan\n3. Functional independence prior to ICH, defined as pre-ICH mRS ≤ 1\n4. NIHSS score ≥ 4 and GCS ≥ 6 upon presentation\n5. Able to commence RIC treatment within 12 hours of stroke onset\n6. Signed and dated informed consent is obtained.\n\nExclusion Criteria:\n\n1. Definite evidence of secondary ICH, such as structural abnormality, brain tumor, thrombolytic drug, and other causes\n2. A very high likelihood that the patient will die within the next 24 hours on the basis of clinical and\u002For radiological criteria\n3. Already booked for surgical treatment\n4. Life expectancy of less than 90 days due to comorbid conditions\n5. Severe hematologic disease\n6. Concurrent use of anticoagulation drugs including Warfarin, dabigatran, rivaroxaban.\n7. Concurrent use of glibenclamide or nicorandil\n8. Any soft tissue, orthopedic, or vascular injury, wounds or fractures in healthy upper limb which may pose a contraindication for application of RIC\n9. Severe hepatic and renal dysfunction\n10. Platelet count \\\u003C100×10\\^9\u002FL\n11. Coagulopathy defined as INR,APTT,and PT beyond the upper limit of normal range\n12. Known pregnancy, or positive pregnancy test, or breastfeeding\n13. Patients being enrolled or having been enrolled in other clinical trial within 3 months prior to this clinical trial\n14. A high likelihood that the patient will not adhere to the study treatment and follow up regimen\n15. Patients unsuitable for enrollment in the clinical trial according to investigators decision making.",{"count":268,"type":22},530,[25],"The purpose of this study is to determine whether treatment with remote ischemic conditioning is of sufficient promise to improve outcome before conducting a larger clinical trial to examine its effectiveness as a treatment for intracerebral hemorrhage.",[272],"Intracranial Hemorrhages",[272,84],{"date":138,"type":37},{"date":276,"type":22},"2026-03-15",{"date":278,"type":22},"2027-06-15",{"name":43,"class":44},{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":287,"targetDuration":289,"studyType":290,"phases":4,"briefSummary":291,"conditions":292,"keywords":295,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":45},"100441475","cerebral-autoregulation-in-patients-with-symptomatic-cerebral-atherosclerotic-stenosis-100441475","NCT05028855","Cerebral Autoregulation in Patients With Symptomatic Cerebral Atherosclerotic Stenosis","CASCAS","Inclusion Criteria:\n\n* Age ranging from 18 to 80, both genders\n* Unilateral internal carotid artery (ICA) or M1 segment of middle cerebral artery (MCA) stenosis (rate of stenosis ranging from 50-99%)\n* Acute ischemic cerebrovascular events (TIA or ischemic stroke) within cerebral stenotic artery supplying area\n* Onset of disease \\\u003C30 d before enrollment\n* Modified Ranking Scale (mRS) ≤1 before stroke onset\n* National Institutes of Health Stroke Scale (NIHSS) ≤20\n* Sufficient bilateral temporal bone windows for insonation of the middle cerebral artery\n* Be conscious, and able to cooperate with CA assessment\n* Willing to participate and sign the informed consent\n\nExclusion Criteria:\n\n* Vertebral artery (VA), basilar artery (BA), anterior cerebral artery (ACA), or posterior cerebral artery (PCA) stenosis; Bilateral internal carotid artery (ICA) or M1 segment of middle cerebral artery (MCA) stenosis(rate of stenosis ranging from 50-99%)\n* Patients who have received or plan to undergo intravascular interventional treatment\u002Fendarterectomy\n* Other intracranial diseases, including cerebral hemorrhage (primary or secondary), intracranial neoplasm, aneurysm, arteriovenous malformation, etc.\n* Evidence for embolic stroke, such as atrial fibrillation, prosthetic valve surgery, and suspected endocarditis, etc.\n* Arrhythmia, anemia and hyperthyroidism which may influence the stability of cerebral blood flow diagnosed by two physicians by electrocardiogram and laboratory tests.\n* Dementia, severe anxiety, depression, and other mental diseases\n* Malignant neoplasm and expected lifetime \\\u003C2 years\n* Enrolled in other clinical trails within 6 months",{"count":288,"type":22},850,"24 Months","OBSERVATIONAL","In this multi-center prospective observational study within a cohort of symptomatic cerebral atherosclerotic stenosis (sCAS) patients, 850 subjects were planed to be enrolled to explore the relationship between cerebral autoregulation (CA) and stroke recurrence, determine the threshold values of CA parameter for predicting stroke recurrence associated with particular stenosis.",[293,294],"Cerebrovascular Stroke","Cerebral Artery Stenosis",[296,297,298,299],"cerebral atherosclerotic stenosis","ischemic stroke","transient ischemic attack","cerebral autoregulation","2024-02-29",{"date":302,"type":37},"2024-03-01",{"date":304,"type":37},"2017-01-14",{"date":306,"type":22},"2026-08-30",{"name":43,"class":44},{"id":309,"slug":310,"hasResults":11,"nctId":311,"briefTitle":312,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":314,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":315,"targetDuration":317,"studyType":290,"phases":4,"briefSummary":318,"conditions":319,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":45},"100506964","application-of-biomarkers-in-neurological-diseases-100506964","NCT05881226","Application of Biomarkers in Neurological Diseases","Inclusion Criteria:\n\n1. Patients with neurological diseases;\n2. Subjects or legal agents agree to participate in the study and sign the informed consent.\n\nExclusion Criteria:\n\n1. Participating in other clinical investigators;\n2. Unwilling to be followed up or poor treatment compliance;\n3. Other conditions considered unsuitable for inclusion by the researchers.",true,{"count":316,"type":22},3000,"1 Year","To explore the predictive and diagnostic role of biomarkers in patients with neurological diseases.",[320],"Biomarkers","2024-02-28",{"date":302,"type":37},{"date":324,"type":37},"2023-06-05",{"date":326,"type":22},"2031-12-01",{"name":43,"class":44},{"id":329,"slug":330,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":4,"eligibilityCriteria":334,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":335,"targetDuration":4,"studyType":23,"phases":337,"briefSummary":338,"conditions":339,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":4},"100526910","effect-of-ginkgo-biloba-extract-on-cognitive-function-in-acute-ischemic-stroke-100526910","NCT06140888","Effect of Ginkgo Biloba Extract on Cognitive Function in Acute Ischemic Stroke","Effect of Ginkgo Biloba Extract on Cognitive Function in Acute Ischemic Stroke: a Multicentre, Randomised, Open-label, Blinded-Endpoint Trial","Inclusion Criteria:\n\n1. Patients with a definitive clinical diagnosis of acute ischemic stroke;\n2. Age≥18 years, regardless of sex；\n3. Primary education level or higher; baseline MoCA score of 10-25 points;\n4. Able to complete cognitive scale scoring;\n5. Informed consent is signed and ginkgo biloba extract therapy is initiated within 14 days of onset.\n\nExclusion Criteria:\n\n1. Transient ischemic attack；\n2. Patients who received emergency reperfusion therapy (including intravenous thrombolysis and endovascular thrombectomy) at onset;\n3. Combined with other neurological diseases, such as neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Lewy body dementia, and frontotemporal dementia), optic neuritis, epilepsy, central nervous system infections (e.g., AIDS and syphilis), traumatic brain injury dementia, etc；\n4. Currently using psychoactive medications (e.g., antidepressants) or anti-epileptic drugs, or if the time since their last use of these medications was less than 5 half-lives (per the pharmacokinetics of each specific medication; for drugs with unknown half-lives, a 1 month washout period was required)；\n5. Had a pre-existing diagnosis of a cognitive disorder；\n6. Currently taking medications intended to improve cognitive function or prevent dementia (e.g., cholinesterase inhibitors, memantine, nootropics), or if the washout period since their last use of these medications was less than 5 half-lives as specified in each drug's pharmacokinetics. For drugs with unknown half-lives, a minimum 1 month washout period was required；\n7. Severe liver and kidney dysfunction;\n8. Active ulcer or bleeding diathesis；\n9. Allergy to preparations containing ginkgo biloba extract；\n10. Pregnant or lactating women, patients with a life expectancy less than 6 months, and those unable to complete the study for other reason；\n11. Unwillingness to be followed up or poor treatment compliance;\n12. Those who are participating in other clinical investigators, or who have participated in other clinical studies within 3 months prior to enrollment;\n13. Other conditions that the investigators deemed unsuitable for enrollment.",{"count":336,"type":22},356,[25],"The purpose of this study is to determine the effect of ginkgo biloba extract on cognitive function in acute ischemic stroke.",[109],"2024-02-25",{"date":321,"type":37},{"date":343,"type":22},"2024-03-15",{"date":345,"type":22},"2027-04-01",{"name":43,"class":44},{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":23,"phases":356,"briefSummary":357,"conditions":358,"keywords":359,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":361,"startDateStruct":362,"completionDateStruct":363,"leadSponsor":365,"locationsCount":45},"100526634","safety-and-efficacy-of-urinary-kallidinogenase-for-large-artery-atherosclerosis-acute-ischemic-stroke-100526634","NCT06137300","Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke","Safety and Efficacy of Urinary Kallidinogenase for Large Artery Atherosclerosis Acute Ischemic Stroke：a Multicentre, Prospective, Randomised, Open-label, Blinded-Endpoint Trial","Inclusion Criteria:\n\n1. Age ≥18 years old;\n2. Acute anterior circulation large artery atherosclerotic cerebral infarction (according to TOAST classification) within 48h of onset; NIHSS score ≥6, ≤15;\n3. Moderate to severe stenosis or occlusion of offending vessels;\n4. The mRS Score ≤2 before onset;\n5. Subjects or their legal representatives agreed to the treatment and signed the informed consent form.\n\nExclusion Criteria:\n\n1. Transient ischemic attack;\n2. Patients who planned or had received emergency reperfusion therapy (including intravenous thrombolysis and emergency thrombectomy);\n3. Severe disturbance of consciousness:GCS ≤8;\n4. Patients who previously received angiotensin-converting enzyme inhibitor (ACEI) drugs regularly;\n5. Refractory hypertension: systolic blood pressure ≥200 mmHg or diastolic blood pressure ≥110 mmHg; hypotension: systolic blood pressure \\\u003C 90 mmHg or diastolic blood pressure \\\u003C 60 mmHg;\n6. Liver dysfunction (ALT\u002FAST \\>1.5 × upper limit of normal \\[ULN\\]), renal dysfunction (Cr \\>1 × ULN);\n7. Coagulopathy (prolonged INR (\\>1.5) or prolonged APTT (\\>2 folds);\n8. Cardioembolic stroke or high-risk factors of cardioembolic stroke identified by investigators (atrial fibrillation, cardiac mural thrombus, cardiomyopathy, etc.);\n9. Special populations such as pregnant and lactating women, patients with life expectancy less than 3 months, or patients unable to complete the study for other reasons;\n10. Unwilling to be followed up or poor treatment compliance;\n11. Participating in other clinical investigators, or had participated in other clinical investigators within 3 months before enrollment;\n12. Other conditions considered by the investigator to be inappropriate for enrollment.",{"count":355,"type":22},986,[25],"The purpose of this study is to evaluate the safety and efficacy of urinary kallidinogenase treatment in patients with large artery atherosclerotic acute ischemic stroke.",[109],[360],"Acute Ischemic Stroke, Urinary Kallidinogenase",{"date":321,"type":37},{"date":343,"type":22},{"date":364,"type":22},"2027-12-31",{"name":43,"class":44},""]